Literature DB >> 2296379

General and dramatic glial reaction in Alzheimer brains.

A Delacourte1.   

Abstract

We quantified glial fibrillary acidic protein (GFAP) using immunoblot techniques and anti-GFAP, in unfractionated homogenates of different brain regions from Alzheimer's disease (AD) patients. The amount of GFAP was significantly higher than in brains from controls and other neurodegenerative disorders (mean of 11 times), even in brain regions usually free of AD lesions such as caudate nucleus, thalamus, cerebellum, or brainstem. This dramatic increase of GFAP is not simply reflective of the astrocytic gliosis usually observed near the neurofibrillary tangles and senile plaques but more likely represents an astrocytic reaction in the whole brain corresponding to an overproduction or an accumulation of GFAP. The significance of such an increase is unknown, but it might be a key element in the pathogenesis of AD.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2296379     DOI: 10.1212/wnl.40.1.33

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  32 in total

Review 1.  Expression profile analysis of neurodegenerative disease: advances in specificity and resolution.

Authors:  Jason G Glanzer; Phillip G Haydon; James H Eberwine
Journal:  Neurochem Res       Date:  2004-06       Impact factor: 3.996

2.  Correlation of astrocytic S100 beta expression with dystrophic neurites in amyloid plaques of Alzheimer's disease.

Authors:  R E Mrak; J G Sheng; W S Griffin
Journal:  J Neuropathol Exp Neurol       Date:  1996-03       Impact factor: 3.685

3.  TNF alpha affects the expression of GFAP and S100B: implications for Alzheimer's disease.

Authors:  M M Edwards; S R Robinson
Journal:  J Neural Transm (Vienna)       Date:  2006-06-01       Impact factor: 3.575

4.  Alzheimer disease periventricular white matter lesions exhibit specific proteomic profile alterations.

Authors:  Eduardo M Castaño; Chera L Maarouf; Terence Wu; Maria Celeste Leal; Charisse M Whiteside; Lih-Fen Lue; Tyler A Kokjohn; Marwan N Sabbagh; Thomas G Beach; Alex E Roher
Journal:  Neurochem Int       Date:  2012-12-08       Impact factor: 3.921

Review 5.  Brain injury and growth inhibitory factor (GIF)--a minireview.

Authors:  I Hozumi; T Inuzuka; S Tsuji
Journal:  Neurochem Res       Date:  1998-03       Impact factor: 3.996

Review 6.  The role of astrocyte mitochondria in differential regional susceptibility to environmental neurotoxicants: tools for understanding neurodegeneration.

Authors:  Laura L Kubik; Martin A Philbert
Journal:  Toxicol Sci       Date:  2015-03       Impact factor: 4.849

7.  Expression of glia maturation factor in neuropathological lesions of Alzheimer's disease.

Authors:  R Thangavel; D Stolmeier; X Yang; P Anantharam; A Zaheer
Journal:  Neuropathol Appl Neurobiol       Date:  2012-10       Impact factor: 8.090

8.  Protective effect of verbascoside in activated C6 glioma cells: possible molecular mechanisms.

Authors:  Emanuela Esposito; Roberto Dal Toso; Giovanna Pressi; Placido Bramanti; Rosaria Meli; Salvatore Cuzzocrea
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-11-11       Impact factor: 3.000

9.  Expression of alpha B-crystallin in Alzheimer's disease.

Authors:  K Renkawek; C E Voorter; G J Bosman; F P van Workum; W W de Jong
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

10.  Serine protease inhibitor antithrombin III and its messenger RNA in the pathogenesis of Alzheimer's disease.

Authors:  R N Kalaria; T Golde; S N Kroon; G Perry
Journal:  Am J Pathol       Date:  1993-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.